Lunresertib/Zedoresertib

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameLunresertib/Zedoresertib

Drug Alias NameDebio2513/Debio0123

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase inhibitorsSerine/threonine-protein kinase WEE1 inhibitors

TargetsMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseSerine/threonine-protein kinase WEE1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesDenmark +[4]

CombinationsYes Lunresertib Zedoresertib

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDebiopharm SA

China Registration ClassN/A

Develop Information

Active CompaniesDebiopharm International Sa

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A